Harvard Apparatus Regenerative Tech Inc  

(Public, NASDAQ:HART)   Watch this stock  
Find more results for JOHN F. MCNAUGHTON
+0.050 (5.87%)
Oct 6 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.85 - 0.90
52 week 0.56 - 7.40
Open 0.88
Vol / Avg. 13,043.00/175,411.00
Mkt cap 10.22M
P/E     -
Div/yield     -
EPS -1.44
Shares 12.02M
Beta     -
Inst. own 29%
Aug 13, 2015
Q2 2015 Harvard Apparatus Regenerative Technology Inc Earnings Call - Webcast
Aug 13, 2015
Q2 2015 Harvard Apparatus Regenerative Technology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -6163.01% -11893.55%
Operating margin -6163.01% -11889.25%
EBITD margin - -11498.92%
Return on average assets -140.44% -99.34%
Return on average equity -232.99% -105.03%
Employees 24 -
CDP Score - -


84 October Hill Rd Ste 11
HOLLISTON, MA 01746-1371
United States - Map
+1-774-2337300 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company making regenerated organs for transplant. The Company's product, the HART-Trachea, is intended to be used to restore the structure and/or function of a severely damaged trachea (windpipe). The HART-Trachea comprises the patient's own bone marrow cells seeded on the Company's InBreath porous plastic scaffold in its InBreath organ bioreactor. Its HART-Trachea addresses both of the challenges to trachea transplant, such as the shortage of suitable donor tracheas and the risk and expense of lifelong anti-rejection drug therapy. The Company has received orphan drug designation from the United States Food and Drug Administration (FDA) for the HART-Trachea in the United States market. The Company is engaged in pre-clinical development of its HART-Trachea.

Officers and directors

John F. Kennedy Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
James J. McGorry President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Thomas McNaughton Jr. Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Saverio La Francesca Chief Medical Officer
Bio & Compensation  - Reuters
David M. Green Director
Age: 50
Bio & Compensation  - Reuters
John J. Canepa Independent Director
Age: 59
Bio & Compensation  - Reuters
Thomas H. Robinson Independent Director
Age: 56
Bio & Compensation  - Reuters